Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR - Institut Pasteur Access content directly
Journal Articles Pharmaceutics Year : 2020

Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR

Abstract

Passive immunotherapy, i.e., treatment with therapeutic antibodies, has been increasingly used over the last decade in several diseases such as cancers or inflammation. However, these proteins have some limitations that single-domain antibodies could potentially solve. One of the main issues of conventional antibodies is their limited brain penetration because of the blood–brain barrier (BBB). In this review, we aim at exploring the different options single-domain antibodies (sDAbs) such as variable domain of heavy-chain antibodies (VHHs) and variable new antigen receptors (VNARs) have already taken to reach the brain allowing them to be used as therapeutic, diagnosis or transporter tools.
Fichier principal
Vignette du fichier
pharmaceutics-12-00937.pdf (681.01 Ko) Télécharger le fichier

Dates and versions

pasteur-03507944 , version 1 (03-01-2022)

Licence

Identifiers

Cite

Elodie Pothin, Dominique Lesuisse, Pierre Lafaye. Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR. Pharmaceutics, 2020, 12 (10), pp.937. ⟨10.3390/pharmaceutics12100937⟩. ⟨pasteur-03507944⟩

Collections

PASTEUR CNRS
29 View
203 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More